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Association of the Sweet-Liking Phenotype and Craving
for AlcoholWith the Response to Naltrexone Treatment
in Alcohol Dependence
A Randomized Clinical Trial
James C. Garbutt, MD; Alexey B. Kampov-Polevoy, MD, PhD; Linda S. Kalka-Juhl, MEd; Robert J. Gallop, PhD
IMPORTANCE Identification of moderators of the response to naltrexone hydrochloride
treatment for alcohol dependence could improve clinical care for patients with alcohol use
disorders.
OBJECTIVE To investigate the preliminary finding that the sweet-liking (SL) phenotype
interacts with a high level of craving for alcohol and is associated with an improved response
to naltrexone in alcohol dependence.
DESIGN, SETTING, AND PARTICIPANTS This 12-week double-blind, randomized,
placebo-controlled clinical trial was conducted from February 1, 2010, to April 30, 2012, in an
academic outpatient medical center. Eighty actively drinking patients were randomized by
the SL (n = 22) or the sweet-disliking (SDL) (n = 58) phenotype and by pretreatment high
(n = 40) or low (n = 40) craving for alcohol, with high craving defined as greater than the
median. Patients and staff were blinded to categorization. Patients were excluded for
unstable medical or psychiatric illness, including dependence on drugs other than nicotine.
Four patients (2 in the placebo arm and 2 in the naltrexone arm) stoppedmedication therapy
because of adverse effects. Data were analyzed from January 15, 2013, to May 15, 2016, based
on intention to treat.
INTERVENTIONS Oral naltrexone hydrochloride, 50mg/d, or daily placebo with weekly to
biweekly brief counseling.
MAIN OUTCOMES ANDMEASURES The a priori hypothesis tested SL/SDL phenotype,
pretreatment craving, and their interaction as moderators of frequency of abstinent and
heavy drinking days during treatment, assessed with the timeline follow-back method.
RESULTS Eighty patients were randomized (57men [71%]; 23 women [29%]; mean [SD] age,
47.0 [8.6] years). A nonsignificant effect of naltrexone on heavy drinking was noted (4.8
fewer heavy drinking days; Cohen d = 0.45; 95% CI, −0.01 to 0.90; F1,67 = 3.52; P = .07). The
SL phenotypemoderated the effect of naltrexone on heavy drinking (6.1 fewer heavy drinking
days; Cohen d = 0.58; 95% CI, 0.12-1.03; F1,67 = 5.65; P = .02) and abstinence (10.0more
abstinent days; Cohen d = 0.57; 95% CI, 0.11-1.02; F1,67 = 5.36; P = .02), and high craving
moderated heavy drinking (7.1 fewer heavy drinking days; Cohen d = 0.66; 95% CI, 0.20-1.11;
F1,67 = 7.37; P = .008). The combination of the SL phenotype and high craving was associated
with a strong response to naltrexone, with 17.1 fewer heavy drinking days (Cohen d = 1.07;
95% CI, 0.58-1.54; F1,67 = 19.33; P < .001) and 28.8more abstinent days (Cohen d = 0.72;
95% CI, 0.25-1.17; F1,67 = 8.73; P = .004) compared with placebo.
CONCLUSIONS AND RELEVANCE The SL phenotype and a high craving for alcohol
independently and particularly in combination are associated with a positive response to
naltrexone. The SL/SDL phenotype and a high craving for alcohol merit further investigation
as factors to identify patients with alcohol dependence who are responsive to naltrexone.
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A lcohol dependence is aprevalent anddamaging illnesswith significant economic and personal costs to fami-lies and society, yet only about 25%of individualswith
alcoholdependencereceive treatment.1Medications to treatal-
coholdependencehavebeendeveloped,but theireffectiveness
hasbeenmodest,withgenerally lowtomediumeffectsizesseen
inunselectedpopulations.2A challenge for clinical research is
to identifymoderators of response.
Severalmoderatorshavebeen tentatively identified in the
literature as positively associatedwith the response to theUS
FoodandDrugAdministration–approvedmedicationnaltrex-
one hydrochloride: high baseline craving for alcohol,3-5 in-
creased density of familial alcohol problems,3,6-8 and the
Asn40Asppolymorphismintheμ-opioidreceptorgene(OPRM1
[rs1799971]).9,10However,noneof these factorshasbeenclearly
demonstrated in prospective trials to moderate naltrexone
response.11 The first published prospective trial of the
Asn40Asp polymorphism reported negative findings.12
Evidence indicates that thehedonic responsetosweet taste
reflects activity of the endogenous opioid system, particu-
larly theμ-opioid system.13-15 Inhumans, hedonic response to
sweet tastegenerallyyields2broad types: thosewho likesweet
taste (SL phenotype) and those who dislike sweet taste (SDL
phenotype).16,17 The SL/SDLphenotypehas been shown to be
stable and heritable18,19 and to be associatedwith the familial
risk for alcohol use disorders.20,21
We hypothesized that hedonic response to sweet taste
might be associated with naltrexone response in individuals
with alcohol dependence. An open-label trial of naltrexone,
50mg/d, in 40patientswith alcohol dependence categorized
as having the SL (n = 15) or the SDL (n = 25) phenotype22
showed that the SL group demonstrated significantly greater
abstinence with higher craving, whereas the SDL group had
less abstinencewithhigher craving. In 2011, Laaksonenet al23
performed a placebo-controlled trial in patients with alcohol
dependence in which the SL phenotype was assessed after
completion of the trial; the investigators found that higher
sweet preference was associatedwith a naltrexone response,
inkeepingwithourhypothesis. Thepresent randomizedclini-
cal trial of naltrexone was designed to prospectively test this
hypothesis and to examine for an interaction between the SL/
SDL phenotype and the craving for alcohol.
Methods
Participants and Screening
Thestudysample consistedof80participantswithalcoholde-
pendence (none fromthepilot study22)whomet inclusionand
exclusion criteria and were randomized to placebo or naltrex-
one (Table and Figure 1). The sample size of 80was calculated
to yield 78.3% power to test a 3-way interaction based on the
pilot study.22 The studywas conducted in outpatient offices at
the University of North Carolina, Chapel Hill, fromFebruary 1,
2010, to April 30, 2012.Men and nonpregnantwomen aged 18
to65yearswhowished to change their drinkingbehaviorwere
recruited from the community. Three hundred patients were
prescreened by telephone. The trial protocol (available in the
Supplement) was approved by the Committee on the Protec-
tion of the Rights of Human Subjects, School of Medicine,
University of North Carolina, Chapel Hill. All participants
providedwritten informed consent.
At the screening visit, participants received a breath alco-
hol test (0.0-g/dL result needed to proceed with the screen-
ing visit). Participants underwentmedical evaluation, includ-
ing blood levels of aspartate aminotransferase, alanine
aminotransferase, γ-glutamyltransferase, bilirubin, and alka-
line phosphatase anda serumpregnancy test. Aurine toxicol-
ogy screen was completed. Individuals also completed a 90-
day timeline follow-back interview24 and the Penn Alcohol
CravingScale (PACS).25Trained interviewers administered the
Mini International Neuropsychiatric Interview26 to deter-
minepsychiatricdiagnoses.Participantswere required tomeet
DSM-IV criteria for alcohol dependence and to consumemore
than 14 (for women) or 21 (formen) standard alcoholic drinks
(defined as 360 mL of beer, 150 mL of wine, or 45 mL of li-
quor) per week, including amean of at least 2 heavy drinking
days per week (men, ≥5 standard drinks per day; women, ≥4
standard drinks per day) during a consecutive 30-day period
within the 90 days before screening. Individuals were ex-
cluded if they had a history of drug dependence other than
nicotineoralcohol in thepastyearor if theyhadapositiveurine
toxicology test result at screening. Participants were allowed
tohave apositive findingof aurine cannabinoid test in the ab-
sence of evidence of cannabinoid dependence. Exclusion cri-
teria consisted of (1) a clinically significantmedical illness; (2)
a significant psychiatric disorder, including depression with
suicidal ideation, bipolar disorder, or schizophrenia; (3) cur-
rent use of a psychotropic medication, including medication
for alcohol dependence,with the exceptionof a stable dose of
anantidepressant exceptmirtazapine for at least 8weeks; and
(4) elevated bilirubin levels, documented cirrhosis, or an ala-
nine aminotransferase or aspartate aminotransferase level
greater than 3.0 times the upper limit of normal.
Overall Study Design
The study was a randomized, double-blind, placebo-
controlled clinical trial with 12 weeks of medication therapy.
Key Points
Question Do the sweet-liking (SL) phenotype and high level of
craving for alcohol moderate the response to naltrexone in
patients with alcohol dependence?
Findings In this randomized clinical trial of 80 patients who were
randomized to naltrexone hydrochloride, 50mg/d, or placebo, the
combination of SL phenotype and a high level of craving for
alcohol was associated with a strong response to naltrexone, with
17.1 fewer heavy drinking days and 28.8more abstinent days
compared with placebo treatment. Patients without the SL
phenotype or a high level of craving did not have a significant
response to naltrexone.
Meaning The SL phenotype and high level of craving for alcohol
may represent practical tools clinicians could use when deciding
whether to prescribe naltrexone for alcohol dependence.
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Table. Demographics of Study Population
Characteristic
Study Group
All Participants SDL Phenotype SL Phenotype
Placebo
(n = 40)
Naltrexone
(n = 40) P Value
Placebo
(n = 29)
Naltrexone
(n = 29) P Value
Placebo
(n = 11)
Naltrexone
(n = 11) P Value
Age, mean (SD), y 48.28 (8.39) 45.78 (8.64) .19 47.72 (8.41) 48.07 (7.92) .87 49.73 (8.58) 39.73 (7.56) .009
Male sex, No. (%) 28 (70) 29 (72.5) .80 19 (65.5) 20 (69) .78 9 (81.8) 9 (81.8) >.99
Married, No. (%) 25 (62.5) 22 (55) .50 19 (65.5) 15 (51.7) .29 6 (54.5) 7 (63.6) .66
Smoker, No. (%) 12 (30) 7 (17.5) .19 7 (24.1) 4 (13.8) .32 5 (45.5) 3 (27.3) .38
Baseline days, mean (SD), %
Heavy drinkinga 0.66 (0.29) 0.64 (0.30) .80 0.65 (0.29) 0.68 (0.30) .71 0.67 (0.31) 0.54 (0.31) .32
Abstinence 0.19 (0.24) 0.14 (0.16) .26 0.17 (0.24) 0.13 (0.17) .47 0.23 (0.25) 0.14 (0.14) .33
PACS score at screening,
mean (SD)
17.28 (5.86) 16.81 (6.22) .73 17.07 (6.28) 17.10 (6.84) .98 17.82 (4.79) 16.00 (4.36) .36
Goal of abstinence, No. (%) 13 (32.5) 11 (28.2) .68 6 (20.7) 8 (28.6) .49 7 (63.6) 3 (27.3) .09
White race, No. (%) 38 (95) 36 (90) .39 28 (96.6) 26 (89.7) .61 10 (90.9) 10 (90.9) >.99
No family history of alcohol
dependence, No. (%)
13 (32.5) 13 (32.5) >.99 11 (37.9) 11 (37.9) >.99 2 (18.2) 2 (18.2) >.99
Age at onset, mean (SD), y 32.13 (11.76) 34.31 (11.30) .41 34.07 (11.26) 37.45 (11.16) .26 27.00 (12.02) 25.91 (6.52) .79
ADS total score, mean (SD)b 14.23 (7.04) 14.75 (6.01) .73 13.34 (6.16) 14.90 (6.67) .36 16.80 (9.03) 14.36 (4.03) .43
CIWA score, mean (SD)c 1.88 (2.11) 2.33 (2.45) .38 1.59 (1.64) 2.52 (2.65) .11 2.64 (3.01) 1.82 (1.83) .45
DRINC total score,
mean (SD)d
25.28 (9.47) 29.35 (8.13) .04 23.90 (7.78) 29.52 (8.11) .009 28.90 (12.66) 28.91 (8.51) >.99
Abbreviations: ADS, Alcohol Dependence Scale; CIWA, Clinical Institute
Withdrawal Assessment; DRINC, Drinker Inventory of Consequences; PACS,
Penn Alcohol Craving Scale; SDL, sweet disliking; SL, sweet liking.
a Defined as at least 5 standard drinks per day for men and at least 4 standard
drinks per day for women.
bScores range from0 to 47, with greater scores indicating a higher level
of alcohol dependence.
cScores range from0 to 67, with greater scores indicating more
withdrawal symptoms.
dScores range from0 to 50, with greater scores indicating more
consequences due to drinking.
Figure 1. CONSORTDiagram
40 Randomized to placebo
108 Participants assessed for eligibility
40 Randomized to naltrexone hydrochloride
11 SL group
10 Received
29 SDL group
29 Received
11 SL group
11 Received
29 SDL group
27 Received
11 Baseline analysis
10 Postbaseline analysis
29 Baseline analysis
29 Postbaseline analysis
11 Baseline analysis
11 Postbaseline analysis
29 Baseline analysis
27 Postbaseline analysis
7 Completed intervention
3 Lost to follow-up
0 Adverse effects
3 Dropouts
21 Completed intervention
8 Lost to follow-up
2 Adverse effects
6 Dropouts
7 Completed intervention
4 Lost to follow-up
0 Adverse effects
4 Dropouts
22 Completed intervention
5 Lost to or unavailable for follow-up
2 Adverse effects
3 Dropouts
80 Participants randomized
28 Excluded
3 Positive urine toxicology result
12 Lack of interest/commitment
4 Do not meet dependence definition
4 Elevated LFT results
2 Elevated bilirubin levels
2 Elevated blood pressure
1 Acute withdrawal symptoms
Active treatment consisted of naltrexone hydrochloride, 50mg/d. LFT indicates liver function tests; SDL, sweet-disliking phenotype; and SL, sweet-liking
phenotype.
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After screening, individuals were encouraged, but not re-
quired, toachieve3daysof sobrietybefore randomization.Par-
ticipants were randomized to oral naltrexone hydrochloride,
50 mg/d, or to matching placebo, with randomization
balanced by SL vs SDL status andhigh vs low levels of craving
(dichotomized for randomizationonlyonmedianPACS scores
from prior trials22) based on a 1:1 algorithm assignment (SAS
software; SAS Institute Inc)within the4 respectiveblockspro-
videdbyoneofus (R.J.G.) TheUniversity ofNorthCarolina In-
vestigational Drug Service assigned participants to interven-
tions basedon the randomization schedule. Participantswere
seenweekly for 3 weeks and then biweekly until week 12.We
used BRENDA,27 a low-intensity counselingmethod, for psy-
chosocial treatment.
Study Procedures
At the initial treatmentvisit (week0) andall subsequent study
visits (weeks 1, 2, 3, 4, 6, 8, 10, and 12), a breath alcohol test
was administered and vital signs were recorded. The revised
Clinical InstituteWithdrawal Assessment for Alcohol Scale28
was administered to assess for symptoms of alcohol with-
drawal.Noonerequiredreferral formedicaldetoxification.Nal-
trexone hydrochloride dosing was titrated from 25 mg/d for
the first 3 days to 50mg/d for the remainder of treatment and
provided in blister packs. Calendars were provided to record
thenumberofpills taken, thenumberofdrinksconsumed,and
any adverse effects of treatment. At weeks 4 and 12 or early
termination, bloodwasdrawn toassess aspartate aminotrans-
ferase, alanine aminotransferase, γ-glutamyltransferase, and
bilirubin values. Pregnancy testing was conducted monthly.
Sweet-Taste Test
At the initial study visit, participants’ sensitivity and hedonic
response to sweet tastewas testedby a research assistantwho
was not involved in any other assessments. Five concentra-
tions of sucrose (0.05, 0.10, 0.21, 0.42, and 0.83M) were pre-
sented in 5 separate blocks for a total of 25 tastings in a pseu-
dorandom order. Participants coded the intensity with “How
strong was the taste?” and the pleasurableness with “How
much do you like the taste?” of each tasting on 200-mm ana-
log line scales.20 The participant and staff involved in assess-
ingandmanaging theparticipantwerekeptblind to the sweet-
taste test results and craving scores until the entire studywas
completed. Participantswere categorizedashavinganSLphe-
notype if they rated the highest concentration of sucrose
(0.83M) as themost pleasurable; otherwise theywere catego-
rized as having an SDL phenotype.20
OutcomeMeasures
Two coprimary drinking outcome measures were selected:
percentage of heavydrinkingdays andpercentage of days ab-
stinent. Tolerability was assessed by records of adverse
effects,dropoutsdue toadverseeffects, laboratoryvalues, and
serious adverse events.
Statistical Analysis
All values are given as the mean (SD) or, for model-based es-
timates, as the estimate followed by the SE, as noted. Model-
based estimates allow for adjustments for variables associ-
atedwithoutcomes, covariates, and complexdesigns, such as
repeated measures. Baseline drinking was defined as drink-
ing during the period that included the 90 days before the
screening visit plus the period between the screening and ini-
tial study visits minus the recommended 3 days of absti-
nence.Themeandurationof thisperiodwas 102 (5)days.Base-
linedifferences indemographic variables and level of baseline
drinking between thenaltrexone andplacebo groupswere in-
vestigated using 2-tailed t tests for continuous variables and
χ2 tests for categorical variables.
The timeline follow-back interviewprovidesweekly scores
ofabstinenceandheavydrinkingforeachparticipantduringthe
12 weeks of medication administration, resulting in hierarchi-
cal levels of clustering (multiple observationswithin eachpar-
ticipant)present inthesedata.Whenthewithin-participantcor-
relation is properly incorporated, the statistical framework
results inanincreaseofstatisticalpowerovermethodsthatcom-
pare groups cross-sectionally.29 We implemented a general
mixed-modelanalysisofvariance (MMANOVA) framework that
models themeans per group over time and the covariance be-
tweentherepeatedmeasuresandhasbeenimplementedinsub-
stanceabuse research.30The terms in theMMANOVAmodel in-
cluded treatment, craving, and thepatient’s SL/SDLstatuswith
the following 3 aims: (1) assessment of the treatment effect; (2)
assessment of the dependency of the treatment effect on pa-
tients craving, as measured by the continuous PACS, and SL/
SDL status, assessed separately; and (3) assessment of the de-
pendencyofthetreatmenteffectonthecombinationofpatients’
cravingandSL/SDLstatus.The first aim isassessed throughthe
maineffects.Thesecondaimisassessedthroughseparate2-way
interactionof treatmentwithin cravingandSL/SDLstatus.The
third aim is assessed through the 3-way interaction of treat-
ment × craving × SL/SDL status. Warnings have been issued
about interpreting analysis resultswhen continuous predictor
variablesaredichotomized.31Allanalyses involvingcravingused
the continuous scale; for simplicity of displaying of higher-
order interaction terms, we used a median split on the ob-
servedPACSscore fromoursample.Sensitivityanalysesofdaily
abstinence and daily heavy alcohol use during themedication
periodanalyzedthroughgeneralizedestimatingequationswere
used to examine the stability of the significant findings from
MMANOVA.32,33Weperformedgoodness-of-fit approaches for
longitudinal datawith assessment for influential observations
and outliers. All analyses were conducted using SAS software
(version 9.4; SAS Institute Inc). Statistical significancewas set
at P < .05 (2-tailed) for all tests based on intention to treat.
Results
Participant Recruitment and Characteristics
Eightyparticipants (57men[71%];23women[29%];mean[SD]
age, 47.0 [8.6] years) were randomized to study treatments.
Figure 1 shows the CONSORT diagram for the trial with 77 of
80 participants for whom we have primary outcome mea-
sures. Thedemographic characteristics of theparticipants are
shownintheTable (for race, individuals self-identifiedaswhite
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orAfricanAmerican). Althoughwe found several baselinedif-
ferences across groups, secondary analyses with these vari-
ables as covariates yielded the samepatternof results as those
without these covariates. Thus, these variables were not in-
cluded as covariates in the analyses reported herein. In addi-
tion, tomaximize statistical power, other variables (eg, sever-
ity of dependence, family history, and smoking) were not
included as covariates owing to the limited sample size.
Primary Outcomes
Percentage of Heavy Drinking Days
Wefoundanonsignificant overall naltrexoneeffect (4.8 fewer
heavy drinking days; Cohen d = 0.45; 95% CI, −0.01 to 0.90;
F1,67 = 3.52;P = .07) onheavy drinking based onweekly sum-
mary scales; a significant interaction of treatment and con-
tinuous craving among participants with higher levels of
craving responding best to naltrexone (7.1 fewer heavy drink-
ing days; Cohen d = 0.66; 95% CI, 0.20-1.11; F1,67 = 7.37;
P = .008); a significant interaction of treatment and SL/SDL
status, with the SL group responding best to naltrexone (6.1
fewer heavy drinking days; Cohen d = 0.58; 95% CI, 0.12-
1.03; F1,67 = 5.65; P = .02); and a significant 3-way interaction
(Cohen d = 0.69; 95% CI, 0.22-1.14; F1,67 = 7.91; P = .006).
Figure 2 presents the estimated proportion of heavy drinking
days perweek for the naltrexone and placebo arms across SL/
SDL status. For presentation purposes, the continuous PACS
score is dichotomized, yielding4 combinationsof craving and
SL/SDL status. The SL subgroup with high craving demon-
strated a marked response to naltrexone compared with
placebo (17.1 fewer heavy drinking days; Cohen d = 1.07; 95%
CI, 0.58-1.54; F1,67 = 19.33; P < .001), whereas no significant
differenceswerenoted in theothergroups.Goodness-of-fit as-
sessments onourMMANOVAdidnot indicate that these find-
ings were driven by 1 or 2 outliers or influential observations.
Sensitivity analysis with the generalized estimating equation
replicated the MMANOVA results, which produced a mar-
ginal treatment × SL/SDLstatus interaction,with theSLgroup
responding best to naltrexone (χ2 = 3.21; P = .07); a signifi-
cant interactionof treatment × craving,withparticipantswith
higher craving responding best to naltrexone (χ2 = 4.59;
P = .03); and a significant 3-way interaction of treat-
ment × craving × SL status (χ2 = 4.57; P = .03).
Percentage of Days Abstinent
We found a nonsignificant treatment (naltrexone) effect on
abstinent days (Cohen d = 0.14; 95% CI, −0.31 to 0.59;
F1,67 = 0.33; P = .56); a nonsignificant interaction of treat-
ment and continuous craving (Cohen d = 0.28; 95% CI, −0.17
to 0.73;F1,67 = 1.29; P = .26); a significant interaction of treat-
ment and SL status, with the SL group responding best to
naltrexone (10.0moreabstinentdays;Cohend = 0.57; 95%CI,
0.11-1.02; F1,67 = 5.36; P = .02); and a significant 3-way inter-
action (Cohend = 0.68;95%CI,0.21-1.13;F1,67 = 7.68;P = .007).
Similar to these findings, Figure 3 presents the estimated
abstinence rates for the naltrexone and placebo arms across
the 4 combinations of craving and SL status, where continu-
ous craving was dichotomized. The SL subgroup with high
craving demonstrated amarked response to naltrexone com-
paredwithplacebo (28.8moreabstinentdays;Cohend = 0.72;
95% CI, 0.25-1.17; F1,67 = 8.73; P = .004), whereas no signifi-
cant differences were noted in the other groups. Goodness-
of-fit assessmentsonourMMANOVAdidnot indicate that these
findings were driven by 1 or 2 outlier or influential observa-
tions. Sensitivity analysis with generalized estimating equa-
tions yielded results similar to our MMANOVAmodel, with a
Figure 2. Effect of Naltrexone Hydrochloride or Placebo on Percentage
of Heavy Drinking Days
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Heavy drinking days are defined as at least 5 standard drinks (defined as 360
mL of beer, 150mL of wine, or 45mL of liquor) per day for men and at least 4
standard drinks per day for women. Results are stratified by the sweet-liking
(SL) phenotype and high alcohol craving status. Individuals with the SL
phenotype and high craving for alcohol demonstrate a robust reduction in
heavy drinking with naltrexone compared with placebo treatment in this
analysis using weekly drinkingmeasures. SDL indicates sweet-disliking
phenotype.
Figure 3. Effect of Naltrexone Hydrochloride or Placebo on Percentage
of Abstinent Days
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Results are stratified by the sweet-liking (SL) phenotype and high alcohol
craving status. Individuals with the SL phenotype and high craving for alcohol
demonstrate a robust increase in abstinent days with naltrexone compared with
placebo in this analysis using weekly drinkingmeasures. SDL indicates
sweet-disliking phenotype.
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significant treatment × SL status interaction, the SL group re-
sponding best to naltrexone (χ2 = 4.60;P = .03), and a signifi-
cant 3-way interaction of treatment × craving × SL status
(χ2 = 5.13; P = .02).
Toassess forevidence that theSLsubgroupwithhighcrav-
ing hadmore robust reduction in cravingwith naltrexone,we
fit the MMANOVA structure on our repeated assessments of
craving.We did not find evidence to support this hypothesis;
rather, participants with SDL and high craving had the most
rapidreductionofcraving (t75 = 2.26;P = .03;Cohend = 0.522),
whereas participants with SL and high craving had the slow-
est. Thepatterns of change in cravingwere similar for naltrex-
one and placebo.
Association Between Treatment Adherence and SL Status
The χ2 test of association indicated no significant difference
betweenthenaltrexoneandplaceboarmswithrespect tomedi-
cation adherence,with 28 of 40participants (70%) in the nal-
trexonearmand33of40participants (82%) in theplaceboarm
reporting no missed doses (χ2 = 1.73; P = .19). Similar pat-
terns are found for the SDL group, with 20 of 29 participants
(69%) in the naltrexone arm and 23 of 29 participants (79%)
in the placebo arm reporting no missed doses (χ2 = 0.81;
P = .37). Among the SL group, 8 of 11 participants (73%) in the
naltrexone arm and 10 of 11 participants (91%) in the placebo
arm reported no missed doses (χ2 = 1.22; P = .27).
Adverse Events
One serious adverse event, a myocardial infarction, was not
attributed to naltrexone treatment. Six participants in each
group reported 1ormore adverse effects,with4patientswith-
drawing attributable to the adverse effects (2 participants in
each treatment arm).
Discussion
Thepresent randomized clinical trial found evidence that the
SL phenotype moderates the response to naltrexone in alco-
hol dependence such that individuals with the SL phenotype
show a significant response to naltrexone and those with the
SDLphenotype showminimal evidence of response. Further-
more, and similar to some prior reports,11 high craving for al-
cohol is associated with a response to naltrexone and, when
combinedwith theSLphenotype, is associatedwith aparticu-
larly robust responsetonaltrexone, leadingtoaclinicallymean-
ingful reduction of 17.1 heavy drinking days and an increase
of 28.8 abstinent days compared with placebo. The popula-
tionwas fairly typical for aUS-basedclinical trial in alcoholde-
pendence,with themedianage in the40sandabout65%base-
line heavy drinking days and being predominately male and
white. Nevertheless, because recruitmentwas based on com-
munity advertising, generalizability to clinical populations is
not ensured.
The present results are consistent with the pilot study
data22 and that reportedbyLaaksonenet al.23 Thus, our study
represents the third clinical study indicating that the SL phe-
notypemay be amoderator of naltrexone response in alcohol
dependence and the second trial indicating an interaction be-
tween craving for alcohol and the SL phenotype. These data
require replication and extension, but the combined results
suggest that the SL/SDL phenotype can provide information
as towhichpatients respondbest tonaltrexoneandwhatneu-
robiological mechanisms may underlie naltrexone response.
If these findings are confirmed, an assessment of the SL/SDL
phenotype could be clinically useful. The phenotype shows
good stability and reproducibility34; is simple, safe, and inex-
pensive to assess; and could evolve as a simple tool tohelp cli-
nicians with medication decisions.
The genetic andneurobiological underpinnings of the SL/
SDLphenotypearenotwellunderstood.Evidencesuggests that
a preference for stronger sweet solutionsmaybe indicative of
a relative opioid deficiency with an accompanying motiva-
tion to seek greater opioid stimulation (eg, higher concentra-
tions of sucrose).13,15 Given that alcohol actively releases
β-endorphin35 and activates the μ-opioid receptor, individu-
alswith the SL phenotypemay bemore susceptible to this re-
warding action of alcohol and most sensitive to pharmaco-
logic agents (eg, naltrexone) that block this action. Although
twin studies18 have demonstrated that about 50%of the vari-
ance in preference for sweets is genetic, the specific genes in-
volved in sweet preference are not well understood. Variants
in the genes coding for the sweet-taste receptor (TAS1R2 and
TAS1R3 [taste receptor type 1, members 2 and 3, respec-
tively]) affect sweet-taste perception, as do other genetic
variations,36 andevidence suggests that variations in the taste
receptor genes affect alcohol intake.36 However, an associa-
tion of these gene variants with naltrexone effects on alcohol
intake has not been studied. How individuals with the SL vs
the SDL phenotype may differ in activation of classic reward
pathways in response to stimuli, such as sucrose or ethanol,
is unclear. Kareken et al37 found that greater activation of
orbitofrontal cortical reward pathways in response to a
strong sucrose solution and greater liking of a strong sucrose
solution was significantly related to higher alcohol con-
sumption; this finding suggests linkage between reward
response to sweets and alcohol use. Phenotypic variation in
reward response pathways to various stimuli should be
investigated further vis-á-vis understanding the response to
naltrexone.
The present study also found that a high craving for alco-
holmoderated reduction inheavydrinkingbynaltrexone.This
finding is consistent with several but not all retrospective re-
ports of craving as a moderator of naltrexone response11 and
a recentanalysisof theCOMBINE (CombiningMedicationsand
Behavioral Interventions for Alcoholism) Study.38 In the pre-
sent trial, we found evidence that the most robust responses
to naltrexone occurred in individuals who had the SL pheno-
type and high craving, whereas those with the SDL pheno-
typeor lowcravingdidnot respond.This associationwas simi-
lar to findings in the pilot study.22 Craving for alcohol is a
complex construct but one thatmay also index aspects of the
endogenous μ-opioid system.39-42 Therefore, a combination
of these2variables—SLphenotypeandhighcraving—mayiden-
tify an endogenous opioid system particularly responsive to
naltrexone.
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Our study has limitations. The distribution of individuals
with the SL/SDLphenotypewas uneven,with an SL:SDL ratio
of about 1:3. Therefore, the total number of participants in the
SL group (n = 22) is small. However, because cravingwas ana-
lyzedas a continuousmeasure, the smallest cell sizewas 11 for
theSLplaceboandnaltrexonegroups,which is consideredad-
equate forour analyses.Nevertheless, the total numberofpar-
ticipants in thepresent studyand the2prior studies22,23 is 198,
so replication of the finding in larger samples is essential.
Conclusions
The results of thepresent trial support thehypothesis that the
SL phenotype is amoderator of the response to naltrexone in
alcoholdependenceand that this effect ismost apparent in the
presence of a high subjective craving for alcohol. Larger clini-
cal trials indiversepopulationsof individualswith alcohol de-
pendence will be necessary to confirm these findings.
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